# US 2025/0152684 A1 · Anti-Alpha-Synuclein Therapeutic Vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152684 A1
- Document ID: US20250152684A1
- Status: Published application
- Kind: A1
- Application number: 18/836,298
- Filed: 2023-02-09
- Published: 2025-05-15
- Earliest claimed: 2022-02-09
- Assignees: AC Immune SA
- Applicants: AC Immune SA
- Inventors: Andrea Pfeifer; Maxime Ayer
- Web page: https://patentgrep.com/patent/US20250152684A1

## CPC

- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a liposomal vaccine composition comprising: a peptide antigen displayed on the surface of the liposome; a peptide comprising a T-cell epitope; and an adjuvant; wherein the peptide antigen comprises, consists essentially of or consists of the structure: X1-X2-X3-E-X4-X5-P-V-D-P-D-N-E-X6, wherein: E is glutamic acid, P is proline; V is Valine, D is aspartic acid, N is asparagine; X1 is present or not and, if present, is G, wherein G is glycine; X2, is present or not and, if present, is G, wherein G is defined as above; X3 is L, K, or S, wherein L is leucine, K is lysine, and S is serine; X4 is D, K or S, wherein D, K and S are as defined above; X5 is M, wherein M is methionine or methionine sulfoxide; X6 is A, K or S, wherein A is alanine and K, and S are as defined above; with the proviso that X3-E-X4-X5-P-V-D-P-D-N-E-X6 is not L-E-D-M-P-V-D-P-D-N-E-A, and which comprises between 1 and 5 amino acid differences compared with the amino acid sequence G-I-L-E-D-M-P-V-D-P-D-N-E-A, and wherein the peptide antigen does not comprise the dipeptide Y-E immediately following X6, wherein Y is tyrosine and E is as defined above.

## Claims

### Claim 1

A liposomal vaccine composition comprising:
a. A peptide antigen displayed on the surface of the liposome;
b. A peptide comprising a T-cell epitope; and
c. An adjuvant;
wherein the peptide antigen comprises, consists essentially of or consists of the structure:
X1-X2-X3-E-X4-X5-P-V-D-P-D-N-E-X6,
wherein:
E is glutamic acid, P is proline; V is Valine, D is aspartic acid, N is asparagine;
X1 is present or not and, if present, is G, wherein G is glycine;
X2, is present or not and, if present, is G, wherein G is defined as above;
X3 is L, K, or S, wherein L is leucine, K is lysine, and S is serine;
X4 is D, K or S, wherein D, K and S are as defined above;
X5 is M, wherein M is methionine or methionine sulfoxide;
X6 is A, K or S, wherein A is alanine and K, and S are as defined above;
with the proviso that X3-E-X4-X5-P-V-D-P-D-N-E-X6 is not L-E-D-M-P-V-D-P-D-N-E-A,
and which comprises between 1 and 5 amino acid differences compared with the amino acid sequence G-I-L-E-D-M-P-V-D-P-D-N-E-A,
and wherein the peptide antigen does not comprise the dipeptide Y-E immediately following X6, wherein Y is tyrosine and E is as defined above.

### Claim 2 (depends on 1)

The liposomal composition of claim 1 wherein X1 and X2 are present.

### Claim 3 (depends on 1)

The liposomal composition of claim 1 wherein X1 and X2 are absent.

### Claim 4 (depends on 1, 2, 3)

The liposomal composition of any one of claims 1 to 3, wherein X5 is methionine sulfoxide.

### Claim 5 (depends on 1, 2, 3, 4)

The liposomal composition of any one of claims 1 to 4, wherein X6 is A or S.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The liposomal composition of any one of claims 1 to 5, wherein X3 is L or K.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The liposomal composition of any one of claims 1 to 6, wherein X4 is D or S.

### Claim 8 (depends on 1)

The liposomal composition of claim 1 wherein the peptide antigen is selected from the group consisting of GGKESMPVDPDNEA (SEQ ID NO: 2), GGKEDMPVDPDNEA (SEQ ID NO: 3), LESMPVDPDNES (SEQ ID NO: 4), LEKMPVDPDNEA (SEQ ID NO: 5), GGSESMPVDPDNEA (SEQ ID NO: 6), GGSESMPVDPDNES (SEQ ID NO: 7), KEDMPVDPDNEA (SEQ ID NO: 8), SESMPVDPDNEA (SEQ ID NO: 9), LESMPVDPDNEA (SEQ ID NO: 10), GGKESMPVDPDNES (SEQ ID NO: 11), KESMPVDPDNEA (SEQ ID NO: 12), KESMPVDPDNES (SEQ ID NO: 13), SEKMPVDPDNEA (SEQ ID NO: 14), LEKMPVDPDNES (SEQ ID NO: 15), GGSESMPVDPDNEK (SEQ ID NO: 16), LEKMPVDPDNEK (SEQ ID NO: 17), GGKEKMPVDPDNEA (SEQ ID NO: 18), GGKESMPVDPDNEK (SEQ ID NO: 19) and GGKEKMPVDPDNEK (SEQ ID NO: 20).

### Claim 9 (depends on 1)

The liposomal vaccine composition of claim 1, wherein the peptide antigen is selected from the group consisting of GGKESMPVDPDNEA (SEQ ID NO: 2), GGKEDMPVDPDNEA (SEQ ID NO: 3), LESMPVDPDNES (SEQ ID NO: 4) and KESMPVDPDNEA (SEQ ID NO: 12).

### Claim 10 (depends on 1)

The liposomal vaccine composition of claim 1, wherein the peptide antigen consists of GGKESMPVDPDNEA (SEQ ID NO: 2).

### Claim 11 (depends on 1)

The liposomal vaccine composition of claim 1, wherein the peptide antigen consists of KESMPVDPDNEA (SEQ ID NO: 12).

### Claim 12

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide antigen further comprises at least one chemical modification.

### Claim 13

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide comprising a T-cell epitope comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 35 (PaDre), SEQ ID NO: 36 (P2), SEQ ID NO: 37 (P30), SEQ ID NO: 21 (SAT13), SEQ ID NO: 22 (SAT15), SEQ ID NO: 23 (SAT17), SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and/or any combination thereof.

### Claim 14

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide comprising a T-cell epitope comprises, consists essentially of or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 29 (SAT42), SEQ ID NO: 30 (SAT43), SEQ ID NO: 31 (SAT44), SEQ ID NO: 32 (SAT47), SEQ ID NO: 35 (PaDre), SEQ ID NO: 36 (P2) and SEQ ID NO: 37 (P30), or a close sequence analogue thereof.

### Claim 15

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide comprising a T-cell epitope comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO: 32 (SAT47) or a close sequence analogue thereof.

### Claim 16

The liposomal vaccine composition of any of the preceding claims, wherein the peptide comprising a T-cell epitope comprises, consists essentially of, or consists of the amino acid sequence SEQ ID NO: 33 (SAT58).

### Claim 17

The liposomal vaccine composition of any one of the preceding claims, wherein the adjuvant comprises a toll-like receptor 4 ligand and/or a toll-like receptor 9 ligand.

### Claim 18 (depends on 17)

The liposomal vaccine composition of claim 17, wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA) and/or wherein the toll-like receptor 9 ligand comprises CpG.

### Claim 19

The liposomal vaccine composition of any one of the preceding claims, wherein the adjuvant comprises monophosphoryl lipid A (MPLA).

### Claim 20

The liposomal vaccine composition of any one of the preceding claims, wherein the adjuvant further comprises CpG.

### Claim 21

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide comprising a T-cell epitope is encapsulated in the liposome.

### Claim 22

A liposomal vaccine composition comprising:
d. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO:12,
e. a peptide comprising a T-cell epitope which comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 24, and/or SEQ ID NO: 25, and/or SEQ ID NO: 27 and
f. an adjuvant; wherein the adjuvant comprises a toll-like receptor 4 ligand, preferably monophosphoryl lipid A (MPLA), and/or a toll-like receptor 9 ligand, preferably CpG.

### Claim 23

A liposomal vaccine composition comprising:
g. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO:12,
h. a peptide comprising a T-cell epitope which comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 46, and/or SEQ ID NO: 25, and/or SEQ ID NO: 27 and
i. an adjuvant; wherein the adjuvant comprises a toll-like receptor 4 ligand, preferably monophosphoryl lipid A (MPLA), and/or a toll-like receptor 9 ligand, preferably CpG.

### Claim 24 (depends on 22, 23)

The liposomal vaccine according to claim 22 or 23, wherein the peptide antigen comprises, consists essentially of, or consist of amino acid sequence SEQ ID NO: 2.

### Claim 25 (depends on 22, 23)

The liposomal vaccine according to claim 22 or 23, wherein the peptide antigen comprises, consists essentially of, or consist of amino acid sequence SEQ ID NO: 12

### Claim 26

A liposomal vaccine composition comprising:
a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID No: 4, SEQ ID NO: 5 or SEQ ID NO: 12; and
b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO: 32 (SAT47) or a close sequence analogue thereof; and
c. an adjuvant; wherein the adjuvant comprises a toll-like receptor 4 ligand; and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA).

### Claim 27

A liposomal vaccine composition comprising:
a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID No: 4, SEQ ID NO: 5 or SEQ ID NO: 12; and
b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO: 33 (SAT58); and
c. an adjuvant; wherein the adjuvant comprises a toll-like receptor 4 ligand; and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA).

### Claim 28 (depends on 26, 27)

The liposomal vaccine composition of claim 26 or 27, wherein the peptide antigen comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3 SEQ ID NO: 4 or SEQ ID NO: 12.

### Claim 29 (depends on 26, 27)

The liposomal vaccine composition of claim 26 or 27, wherein the peptide antigen comprises, consists essentially of or consists of an amino acid sequence SEQ ID NO: 2.

### Claim 30 (depends on 26, 27)

The liposomal vaccine composition of claim 26 or 27, wherein the peptide antigen comprises, consists essentially of or consists of an amino acid sequence SEQ ID NO: 12.

### Claim 31

A liposomal vaccine composition comprising:
a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence SEQ ID NO: 2,
b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO: 32 (SAT47) or a close sequence analogue thereof; and
c. an adjuvant; wherein the adjuvant comprises a toll-like receptor 4 ligand and/or a toll-like receptor 9 ligand; and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA), wherein the toll-like receptor 9 ligand comprises CpG.

### Claim 32

A liposomal vaccine composition comprising:
a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence SEQ ID NO: 2,
b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO: 33 (SAT58) and
c. an adjuvant; wherein the adjuvant comprises a toll-like receptor 4 ligand and/or a toll-like receptor 9 ligand; and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA), wherein the toll-like receptor 9 ligand comprises CpG.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A pharmaceutical composition comprising the liposomal vaccine composition of any one of the claims 1 to 32, and a pharmaceutically acceptable carrier, diluent and/or excipient.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A kit comprising a liposomal vaccine composition as defined in any one of claims 1 to 32 or the pharmaceutical composition of claim 33 and a container.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The liposomal vaccine composition as defined in any one of claims 1 to 32, or pharmaceutical composition as defined in claim 33, or kit as defined in claim 34 for use in the treatment or prevention of diseases, disorders or abnormalities associated with alpha-synuclein aggregates.

### Claim 36 (depends on 35)

The liposomal vaccine composition, pharmaceutical composition or kit for use of claim 35, wherein the disease, disorder or abnormality associated with alpha-synuclein aggregates is a synucleinopathy.

### Claim 37 (depends on 35, 36)

The liposomal vaccine composition, pharmaceutical composition or kit for use of claim 35 or 36, wherein the disease, disorder or abnormality associated with alpha-synuclein aggregates or the synucleinopathy is selected from the group consisting of Parkinson's disease (sporadic, familial with alpha-synuclein mutations, familial with mutations other than alpha-synuclein, pure autonomic failure and Lewy body dysphagia), Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)), diffuse Lewy body disease (DLBD), sporadic Alzheimer's disease, familial Alzheimer's disease with APP mutations, familial Alzheimer's disease with PS-1, PS-2 or other mutations, familial British dementia, Lewy body variant of Alzheimer's disease, and Down syndrome, multiple system atrophy (Shy-Drager syndrome, striatonigral degeneration and olivopontocerebellar atrophy), traumatic brain injury, chronic traumatic encephalopathy, dementia puglistica, tauopathies (Pick's disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration and Niemann-Pick type C1 disease, frontotemporal dementia with Parkinsonism linked to chromosome 17), motor neuron disease, Huntington's disease, amyotrophic lateral sclerosis (sporadic, familial and ALS-dementia complex of Guam), neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type 1 (Hallervorden-Spatz syndrome), prion diseases, Creutzfeldt-Jakob disease, ataxia telangiectatica, Meige's syndrome, subacute sclerosing panencephalitis, Gerstmann-Straussler-Scheinker disease, inclusion-body myositis, Gaucher disease, Krabbe disease as well as other lysosomal storage disorders (including Kufor-Rakeb syndrome and Sanfilippo syndrome) and rapid eye movement (REM) sleep behavior disorder.

### Claim 38 (depends on 35, 36, 37)

The liposomal vaccine composition, pharmaceutical composition or kit for use according to any one of claims 35 to 37, wherein the disease, disorder or abnormality associated with alpha-synuclein aggregates or the synucleinopathy is selected from the group consisting Lewy bodies and/or Lewy neurites and/or glial cytoplasmic inclusions, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)), or Diffuse Lewy Body Disease.

### Claim 39 (depends on 35, 36, 37)

The liposomal vaccine composition, pharmaceutical composition or kit for use according to any one of claims 35 to 37, wherein the disease, disorder or abnormality associated with alpha-synuclein aggregates or the synucleinopathy is Multiple System Atrophy.

### Claim 40 (depends on 35, 36, 37)

The liposomal vaccine composition, pharmaceutical composition or kit for use according to claims 35 to 37, wherein the disease, disorder or abnormality associated with alpha-synuclein aggregates or the synucleinopathy is Parkinson's disease.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method for prophylaxis, treatment and alleviation of diseases associated with the disease, disorder or abnormality associated with alpha-synuclein aggregates; wherein the method comprises administering to the subject the liposomal vaccine composition of any one of claims 1 to 32 or the pharmaceutical composition of claim 33.

### Claim 42 (depends on 41)

The method of claim 41, wherein the disease, disorder or abnormality associated with alpha-synuclein aggregates is a synucleinopathy.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 41, 42)

The method of any claim 41 or 42, wherein administering to the subject the liposomal vaccine composition of any one of claims 1 to 32 or the pharmaceutical composition of claim 33 induces an immune response against alpha-synuclein aggregates.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 41, 42)

The method of any claim 41 or 42, wherein administering to the subject the liposomal vaccine composition of any one of claims 1 to 32 or the pharmaceutical composition of claim 33 induces a protective immune response against alpha-synuclein aggregates.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 41, 42)

The method of any claim 41 or 42, wherein the administering to the subject the liposomal vaccine composition of any one of claims 1 to 32 or the pharmaceutical composition of claim 33 induces an immune response against alpha-synuclein protein, preferably human alpha-synuclein protein.
